慢性肾脏病患者及肾移植受者的丙型肝炎病毒治疗
Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients.
作者信息
Corson Melissa, Moch Ashley, Saab Sammy
机构信息
Dr Corson is a medical resident in the Department of Medicine at the University of California at Los Angeles in Los Angeles, California. Ms Moch is a research assistant in the Department of Surgery at the University of California at Los Angeles. Dr Saab is a professor in the Departments of Medicine and Surgery at the University of California at Los Angeles.
出版信息
Gastroenterol Hepatol (N Y). 2018 May;14(5):280-285.
Abstract
An important interplay exists between hepatitis C virus (HCV) infection and chronic kidney disease (CKD). HCV infection is associated with an increased risk of morbidity and mortality in patients coinfected with CKD, and patients with CKD have an increased risk of HCV infection. Direct-acting antiviral (DAA) agents have changed the landscape of treatment with excellent sustained virologic response rates and fewer side effects than previously seen. An increasing number of studies demonstrate that DAA agents are efficacious and safe both in patients on dialysis and in patients who have undergone kidney transplantation. This article reviews the current literature on approved DAA agents for the treatment of HCV infection in patients on dialysis and in kidney transplant recipients.
摘要
丙型肝炎病毒（HCV）感染与慢性肾脏病（CKD）之间存在重要的相互作用。HCV感染会增加CKD合并感染患者的发病和死亡风险，而CKD患者感染HCV的风险也会增加。直接抗病毒（DAA）药物改变了治疗格局，其持续病毒学应答率优异，且副作用比以往更少。越来越多的研究表明，DAA药物在透析患者和肾移植患者中均有效且安全。本文综述了目前关于已获批用于治疗透析患者和肾移植受者HCV感染的DAA药物的文献。
相似文献
1
Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients.慢性肾脏病患者及肾移植受者的丙型肝炎病毒治疗
Gastroenterol Hepatol (N Y). 2018 May;14(5):280-285.
2
Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update.从丙型肝炎病毒感染供体向未感染受者移植肾脏：KDIGO 2022 丙型肝炎临床实践指南更新的系统评价。
Am J Kidney Dis. 2023 Oct;82(4):410-418. doi: 10.1053/j.ajkd.2022.12.019. Epub 2023 Apr 14.
3
Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience.直接作用抗病毒疗法在肾移植受者中清除丙型肝炎病毒感染：卡塔尔经验。
Immun Inflamm Dis. 2021 Mar;9(1):246-254. doi: 10.1002/iid3.386. Epub 2020 Dec 2.
4
Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories.慢性丙型肝炎与慢性肾脏病：进展、局限与未知领域
J Viral Hepat. 2017 Jun;24(6):442-453. doi: 10.1111/jvh.12681. Epub 2017 Feb 22.
5
Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation.慢性肾脏病及肾移植背景下丙型肝炎病毒感染的管理进展
Gastroenterol Hepatol (N Y). 2018 Dec;14(12):687-705.
6
Hepatitis C virus and the kidney.丙型肝炎病毒与肾脏。
Nat Rev Nephrol. 2019 Feb;15(2):73-86. doi: 10.1038/s41581-018-0081-8.
7
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.直接作用抗病毒药物在慢性丙型肝炎病毒感染肾移植受者中的疗效与安全性
PLoS One. 2016 Jul 14;11(7):e0158431. doi: 10.1371/journal.pone.0158431. eCollection 2016.
8
Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.丙型肝炎病毒阳性供者肾移植术后早期应用直接抗病毒药物治疗丙型肝炎病毒感染受者:单中心回顾性研究。
Transpl Int. 2017 Sep;30(9):865-873. doi: 10.1111/tri.12954. Epub 2017 May 2.
9
Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.直接作用抗病毒治疗时代前后 HIV/HCV 合并感染肾移植受者的临床结局：10 年单中心经验。
Clin Transplant. 2019 May;33(5):e13532. doi: 10.1111/ctr.13532. Epub 2019 Apr 4.
10
A systematic review of direct acting antiviral therapies in hepatitis C virus-negative liver transplant recipients of hepatitis C-viremic donors.对丙型肝炎病毒血症供体的丙型肝炎病毒阴性肝移植受者直接抗病毒疗法的系统评价。
Pharmacotherapy. 2022 Dec;42(12):905-920. doi: 10.1002/phar.2742. Epub 2022 Nov 25.
引用本文的文献
1
[Sustained virologic response in patients with hepatitis C and chronic kidney disease].丙型肝炎合并慢性肾脏病患者的持续病毒学应答
Rev Med Inst Mex Seguro Soc. 2022 May 2;60(3):283-288.
2
Eliminating viral hepatitis in children after liver transplants: How to reach the goal by 2030.在肝移植后消除儿童中的病毒性肝炎：如何在 2030 年前实现这一目标。
World J Gastroenterol. 2022 Jan 21;28(3):290-309. doi: 10.3748/wjg.v28.i3.290.
3
Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study.肾移植和血液透析患者的真实世界直接抗病毒治疗：EpiTer-2多中心观察性研究
Ann Gastroenterol. 2021;34(3):438-446. doi: 10.20524/aog.2021.0595. Epub 2021 Feb 5.
4
Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.直接抗病毒药物在维持性血液透析合并慢性丙型肝炎患者中的有效性
Medicine (Baltimore). 2020 Nov 25;99(48):e23384. doi: 10.1097/MD.0000000000023384.
5
The Psychosocial Burden of HCV Infection and the Impact of Antiviral Therapy on the Quality of Life in Liver and Kidney Transplant Recipients: A Pilot Study.丙型肝炎病毒感染对肝和肾移植受者的心理社会负担及抗病毒治疗对其生活质量的影响：一项初步研究
Gastroenterol Res Pract. 2020 Nov 3;2020:8754247. doi: 10.1155/2020/8754247. eCollection 2020.
本文引用的文献
1
OPTN/SRTR 2016 Annual Data Report: Liver.OPTN/SRTR 2016 年度数据报告：肝脏。
Am J Transplant. 2018 Jan;18 Suppl 1:172-253. doi: 10.1111/ajt.14559.
2
Direct-Acting Antivirals in Kidney Transplant Patients: Successful Hepatitis C Treatment and Short-Term Reduction in Urinary Protein/Creatinine Ratios.肾移植患者中的直接作用抗病毒药物：丙型肝炎的成功治疗及尿蛋白/肌酐比值的短期降低
Pathog Immun. 2017;2(3):366-375. doi: 10.20411/pai.v2i3.211. Epub 2017 Sep 19.
3
Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection.直接抗病毒药物（DAA）——丙型肝炎病毒感染治疗的新时代。
Pharmacol Ther. 2018 Mar;183:118-126. doi: 10.1016/j.pharmthera.2017.10.009. Epub 2017 Oct 10.
4
The rise of the opioid epidemic and hepatitis C-positive organs: A new era in liver transplantation.阿片类药物流行和丙型肝炎阳性器官的兴起：肝移植的新时代。
Hepatology. 2018 Apr;67(4):1600-1608. doi: 10.1002/hep.29572. Epub 2018 Mar 4.
5
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.格卡瑞韦和哌仑他韦治疗丙型肝炎病毒合并严重肾功能损害患者。
N Engl J Med. 2017 Oct 12;377(15):1448-1455. doi: 10.1056/NEJMoa1704053.
6
Long-term Patient and Graft Survival of Kidney Transplant Recipients With Hepatitis C Virus Infection in the United States.美国丙型肝炎病毒感染肾移植受者的长期患者和移植物存活率。
Transplantation. 2018 Mar;102(3):454-460. doi: 10.1097/TP.0000000000001953.
7
When and how can nephrologists treat hepatitis C virus infection in dialysis patients?肾病专家何时以及如何治疗透析患者的丙型肝炎病毒感染？
Semin Dial. 2018 Jan;31(1):26-36. doi: 10.1111/sdi.12650. Epub 2017 Sep 18.
8
Transplanting HCV-Infected Kidneys into Uninfected Recipients.将感染丙型肝炎病毒的肾脏移植给未感染的受者。
N Engl J Med. 2017 Sep 14;377(11):1105. doi: 10.1056/NEJMc1709315.
9
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.当前直接作用抗病毒方案在丙型肝炎肾移植和肝移植受者中的安全性和有效性：HCV-TARGET研究结果
Hepatology. 2017 Oct;66(4):1090-1101. doi: 10.1002/hep.29258. Epub 2017 Sep 4.
10
Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study.丙型肝炎病毒载量、基因型与终末期肾病发病风险增加：REVEAL-HCV 研究。
Hepatology. 2017 Sep;66(3):784-793. doi: 10.1002/hep.29192. Epub 2017 Jul 18.
Zotero 插件